Inspire Medical Systems (NYSE:INSP) Reports Bullish Q2 CY2026, Stock Jumps 13.6%
Inspire Medical Systems (NYSE:INSP) reported Q2 CY2026 revenue of $200.6 million, down 7.6% year over year but above market expectations by 3%. Full-year revenue guidance is $855 million at the midpoint, 1.4% above estimates. Non-GAAP EPS was $0.14, above consensus. Shares rose 13.6% to $59.28 after the release.
How this was made
The 30-second read
Why it matters
Q2 results beat revenue and EPS expectations, and full-year revenue guidance at the midpoint ($855M) came in above analysts’ estimates, while YoY revenue still fell 7.6%. Adjusted operating margin expanded to 15.3% and the stock reportedly jumped 13.6% to $59.28 immediately after the report.
Market read
Traders can reassess near-term expectations after a fresh earnings and guidance print that beat consensus on revenue and EPS, alongside margin expansion.
What to watch
The article emphasizes margin improvement and guidance outperformance, but does not quantify the magnitude of reimbursement/coding headwinds or provide segment-level drivers that could explain the YoY revenue drop.
Background
Inspire Medical Systems sells an implantable neurostimulation therapy for obstructive sleep apnea as an alternative to CPAP.
Ticker impact
Inspire Medical Systems reported Q2 CY2026 revenue of $200.6M (down 7.6% YoY) but beat expectations, with non-GAAP EPS of $0.14 and full-year revenue guidance of $855M midpoint.
Likely supports continued upside bias after the reported 13.6% jump, but follow-through may depend on whether the next-12-month revenue/EPS contraction expectations prove too pessimistic.
The article provides concrete earnings and guidance datapoints (Q2 beat, FY revenue guidance 1.4% above estimates, adjusted EPS $0.14) and notes the stock jumped 13.6% immediately after reporting, indicating the market treated the print as a fresh catalyst.
Market effects
Reinforces demand and margin leverage narrative in implantable sleep apnea devices, though YoY revenue decline highlights reimbursement/coding sensitivity.
Primarily US-listed healthcare medtech sentiment; limited direct regional spillover described.
No explicit global expansion or international regulatory developments mentioned.
Counterpoint
Despite the beat, the company still guided toward revenue and EPS declines over the next 12 months, suggesting the rally could fade if investors focus on contraction.
Key entities
- companyInspire Medical Systems
Reported Q2 CY2026 results, provided full-year revenue guidance, and saw shares jump 13.6% after the release.
- executiveTim Herbert
Chairman and CEO quoted on discipline, reimbursement environment, and long-term adoption of Inspire therapy.
